Alpha Fusion and Curadh MTR Form Strategic Partnership for Astatine-211 Radiopharmaceuticals Development

Alpha Fusion, Inc., a leader in Astatine-211 (At-211) drug discovery, has announced a strategic partnership with Curadh MTR Inc., a company renowned for its expertise in radiopharmaceutical development. This collaboration aims to advance the global development of At-211-based radiopharmaceuticals, with both organizations pooling their strengths to create a joint venture focused on the clinical development and expansion of At-211 products. The announcement was made during the World Astatine Community Meeting, where the therapeutic potential of At-211 was emphasized by the scientific and clinical founders from both companies.

The joint venture is set to spotlight clinical development in the United States while also working on creating a comprehensive pipeline of At-211 products. Tadashi Watabe, M.D., Ph.D., FANMB, from the Department of Radiology at the Graduate School of Medicine, University of Osaka, shared insights into the progress of clinical trials in Osaka, reflecting the pioneering research being conducted in Japan. Dr. Alison Armour, Founder and CMO of Curadh, elaborated on the significance of Astatine for the future of molecularly targeted radiopharmaceuticals, underlining its potential as a pivotal element in next-generation cancer therapies.

Sunao Fujioka, CEO of Alpha Fusion, expressed enthusiasm for the partnership, highlighting the company's efforts in building an efficient supply chain for At-211 through collaboration with global partners. This includes utilizing cyclotrons and GMP manufacturing processes to streamline production. The partnership with Curadh is expected to significantly accelerate Alpha Fusion's expansion into the US and global markets, leveraging Curadh's deep expertise in radiopharmaceutical development.

Glenn Kazo, CEO of Curadh, noted that the alliance with Alpha Fusion enhances Curadh’s position in next-generation radiopharmaceuticals. Astatine's unique properties, including its role as a halogen emitter with a short half-life, make it a promising candidate for molecularly targeted cancer therapy, offering innovative solutions for oncological treatments.

Alpha Fusion Inc., established to commercialize Astatine drug discovery, is committed to exploring the therapeutic potential of Astatine therapy within the rapidly progressing field of Targeted Alpha Therapy. Their efforts are rooted in research from Osaka University and the Japan Science and Technology Agency, aiming to revolutionize cancer treatment methods.

Curadh MTR, Inc., on the other hand, focuses on advancing second-generation radiopharmaceuticals through innovative drug design and strategic partnerships that integrate novel targets and new radioisotopes. Founded by Dr. Alison Armour, who spearheaded the clinical development of Pluvicto®, Curadh is led by a team of experts dedicated to enhancing MTR development.

As Alpha Fusion and Curadh embark on their collaborative journey, the focus remains on leveraging their combined expertise to develop groundbreaking At-211-based therapies that promise to transform the landscape of cancer treatment. Both companies are poised to make significant contributions to the field of radiopharmaceuticals, offering hope for more effective and targeted cancer therapies in the future.